Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 Plus Everolimus in Refractory Metastatic Pancreatic Adenocarcinoma
NCT02985125Phase 2Completed
- Sponsor
- Georgetown University
- Start
- May 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib in pancreatic adenocarcinoma (PDAC) (5 arms), sponsored by Georgetown University. Primary endpoints: Recommended Phase II Dose at 4 weeks and Progression-free Survival Rate at 8 weeks. Started May 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02985125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985125.